Alpha Tau Medical Ltd. Overview
Pro stress-test →Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT® for the treatment of solid tumors. Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.
Strategic Profile
Pro stress-test →The company is experiencing rapid expansion of business activities, including four parallel trial approvals in the U.S., expansion into trials in multiple internal organs, and continued expansion of manufacturing capacity and pre-commercial preparations. In April 2025, the company closed a $36.9 million offering and intends to use proceeds for general corporate purposes, including R&D, manufacturing expansion, and potential commercialization of product candidates.
Competitive Landscape
Pro stress-test →Alpha Tau operates in the precision oncology radiation therapy space with limited direct competitors. The company's unique alpha-particle approach differentiates it from conventional external beam radiotherapy and brachytherapy providers. Indirect competition exists from established radiation oncology platforms and emerging targeted cancer therapies, though Alpha DaRT's novel mechanism provides potential competitive advantages.
Industry Context
Alpha Tau Medical Ltd. operates in Oncology Therapeutics / Medical Devices.
Key facts
Founded: 2015 · Headquarters: Jerusalem, Israel